Vaccination against zoster remains effective in older adults who later undergo chemotherapy
- PMID: 25097079
- DOI: 10.1093/cid/ciu498
Vaccination against zoster remains effective in older adults who later undergo chemotherapy
Abstract
Background: Approximately 40% of adults develop invasive cancer during their lifetimes, many of whom require chemotherapy. Herpes zoster (HZ) is common and often severe in patients undergoing chemotherapy, yet there are no data regarding whether these patients retain specific protection against HZ if they had previously received zoster vaccine. We conducted a study to determine whether zoster vaccine was effective in patients who subsequently underwent chemotherapy.
Methods: The cohort study consisted of Kaiser Permanente Southern California members aged ≥60 years treated with chemotherapy. The exposure variable was receipt of zoster vaccine prior to initiation of chemotherapy. Incident HZ cases were identified using International Classification of Diseases, Ninth Revision diagnostic codes. HZ incidence rates were calculated; hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models.
Results: There were 91 and 583 HZ cases in the vaccinated and unvaccinated cohorts, respectively, yielding an incidence rate of 12.87 (95% CI, 10.48-15.80) vs 22.05 (95% CI, 20.33-23.92) per 1000 person-years. Thirty-month cumulative incidence was 3.28% in the vaccinated group and 5.34% in the unvaccinated group (P < .05). The adjusted HR for HZ was 0.58 (95% CI, .46-.73) and showed no significant variation by age, sex, or race. HZ incidence rates remained increased in the small subgroup of persons receiving zoster vaccine within 60 days before chemotherapy, but this was the only group affected by indication bias. No vaccinated patients underwent hospitalization for HZ, compared with 6 unvaccinated patients.
Conclusions: Zoster vaccine continues to protect against HZ if recipients later undergo chemotherapy. Our findings provide an additional rationale for offering zoster vaccine to indicated adults while they are immunocompetent.
Keywords: chemotherapy; immunosuppression; vaccine effectiveness; zoster vaccine.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Comment in
-
Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.Clin Infect Dis. 2014 Oct;59(7):920-2. doi: 10.1093/cid/ciu501. Epub 2014 Aug 4. Clin Infect Dis. 2014. PMID: 25097080 No abstract available.
Similar articles
-
Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.Vaccine. 2011 May 9;29(20):3628-32. doi: 10.1016/j.vaccine.2011.03.018. Epub 2011 Mar 22. Vaccine. 2011. PMID: 21435407
-
Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease.Clin Infect Dis. 2016 Feb 15;62(4):462-7. doi: 10.1093/cid/civ930. Epub 2015 Dec 14. Clin Infect Dis. 2016. PMID: 26671505
-
Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.J Infect Dis. 2012 Jul 15;206(2):190-6. doi: 10.1093/infdis/jis334. Epub 2012 Jun 4. J Infect Dis. 2012. PMID: 22669900
-
Vaccination: a new option to reduce the burden of herpes zoster.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Expert Rev Vaccines. 2010. PMID: 20192716 Review.
-
[Herpes Zoster and its prevention in Italy. Scientific consensus statement].Ig Sanita Pubbl. 2014 Jan-Feb;70(1):111-27. Ig Sanita Pubbl. 2014. PMID: 24770367 Italian.
Cited by
-
Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study.Vaccines (Basel). 2023 Jan 25;11(2):259. doi: 10.3390/vaccines11020259. Vaccines (Basel). 2023. PMID: 36851138 Free PMC article.
-
Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.Front Immunol. 2022 Sep 30;13:978203. doi: 10.3389/fimmu.2022.978203. eCollection 2022. Front Immunol. 2022. PMID: 36248796 Free PMC article.
-
Aging and Options to Halt Declining Immunity to Virus Infections.Front Immunol. 2021 May 12;12:681449. doi: 10.3389/fimmu.2021.681449. eCollection 2021. Front Immunol. 2021. PMID: 34054872 Free PMC article. Review.
-
Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis.BMJ Open. 2020 Jan 29;10(1):e034886. doi: 10.1136/bmjopen-2019-034886. BMJ Open. 2020. PMID: 32001495 Free PMC article.
-
Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.Clin Infect Dis. 2020 Oct 23;71(7):e125-e134. doi: 10.1093/cid/ciz1090. Clin Infect Dis. 2020. PMID: 31677266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
